Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

251 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics.
Yamori T. Yamori T. Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S74-9. doi: 10.1007/s00280-003-0649-1. Epub 2003 Jun 18. Cancer Chemother Pharmacol. 2003. PMID: 12819939 Review.
In vitro cytotoxicity of the protoberberine-type alkaloids.
Iwasa K, Moriyasu M, Yamori T, Turuo T, Lee DU, Wiegrebe W. Iwasa K, et al. Among authors: yamori t. J Nat Prod. 2001 Jul;64(7):896-8. doi: 10.1021/np000554f. J Nat Prod. 2001. PMID: 11473418
ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms.
Kong D, Yamori T. Kong D, et al. Among authors: yamori t. Cancer Sci. 2007 Oct;98(10):1638-42. doi: 10.1111/j.1349-7006.2007.00580.x. Epub 2007 Aug 16. Cancer Sci. 2007. PMID: 17711503
Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase.
Kong D, Yaguchi S, Yamori T. Kong D, et al. Among authors: yamori t. Biol Pharm Bull. 2009 Feb;32(2):297-300. doi: 10.1248/bpb.32.297. Biol Pharm Bull. 2009. PMID: 19182393
Search for novel anti-tumor agents from ridaifens using JFCR39, a panel of human cancer cell lines.
Guo WZ, Wang Y, Umeda E, Shiina I, Dan S, Yamori T. Guo WZ, et al. Among authors: yamori t. Biol Pharm Bull. 2013;36(6):1008-16. doi: 10.1248/bpb.b13-00129. Epub 2013 Apr 9. Biol Pharm Bull. 2013. PMID: 23575219
Development of an immunohistochemical protein quantification system in conjunction with tissue microarray technology for identifying predictive biomarkers for phosphatidylinositol 3-kinase inhibitors.
Isoyama S, Yoshimi H, Dan S, Okamura M, Seki M, Irimura T, Yamori T. Isoyama S, et al. Among authors: yamori t. Biol Pharm Bull. 2012;35(9):1607-13. doi: 10.1248/bpb.b12-00327. Biol Pharm Bull. 2012. PMID: 22975517
AMF-26, a novel inhibitor of the Golgi system, targeting ADP-ribosylation factor 1 (Arf1) with potential for cancer therapy.
Ohashi Y, Iijima H, Yamaotsu N, Yamazaki K, Sato S, Okamura M, Sugimoto K, Dan S, Hirono S, Yamori T. Ohashi Y, et al. Among authors: yamori t. J Biol Chem. 2012 Feb 3;287(6):3885-97. doi: 10.1074/jbc.M111.316125. Epub 2011 Dec 9. J Biol Chem. 2012. PMID: 22158626 Free PMC article.
ZSTK474, a specific phosphatidylinositol 3-kinase inhibitor, induces G1 arrest of the cell cycle in vivo.
Dan S, Okamura M, Mukai Y, Yoshimi H, Inoue Y, Hanyu A, Sakaue-Sawano A, Imamura T, Miyawaki A, Yamori T. Dan S, et al. Among authors: yamori t. Eur J Cancer. 2012 Apr;48(6):936-43. doi: 10.1016/j.ejca.2011.10.006. Epub 2011 Nov 14. Eur J Cancer. 2012. PMID: 22088482
Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39.
Kong D, Dan S, Yamazaki K, Yamori T. Kong D, et al. Among authors: yamori t. Eur J Cancer. 2010 Apr;46(6):1111-21. doi: 10.1016/j.ejca.2010.01.005. Epub 2010 Feb 1. Eur J Cancer. 2010. PMID: 20129775
Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest.
Dan S, Yoshimi H, Okamura M, Mukai Y, Yamori T. Dan S, et al. Among authors: yamori t. Biochem Biophys Res Commun. 2009 Jan 30;379(1):104-9. doi: 10.1016/j.bbrc.2008.12.015. Epub 2008 Dec 16. Biochem Biophys Res Commun. 2009. PMID: 19094964
251 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback